How BW&CO Turned a Borderline NIH SBIR Score Into a Funded Phase I Award

Quick Answer

A life sciences client came to BW&CO Consulting after its NIH Phase I SBIR application received an impact score of 39, a range where applicants are typically advised to prepare for resubmission rather than expect funding. Instead of treating the score as final, BW&CO coached the founder through a strategic meeting with the NIH Program Officer, helped identify new evidence and progress generated since submission, and structured the conversation around the reviewers' specific concerns. The Program Officer's tone shifted over the course of that meeting from cautious to encouraging, and the company went on to receive an official Notice of Award funding its Phase I project. The case illustrates BW&CO's "front door, back door" approach: building a strong proposal for peer review, then working the post-review process through appropriate Program Officer engagement rather than assuming a numeric score is the final word.

The Challenge: A Score That Looked Like a Dead End

A life sciences company engaged BW&CO to support its NIH Phase I SBIR application. When the review came back, the proposal received an impact score of 39. In NIH's percentile-driven review system, a score in that range typically signals that an application falls outside a likely funding zone, and applicants are generally counseled to start preparing for resubmission in a future cycle.

The founder read the score the way most first-time or infrequent NIH applicants do. He assumed the application was effectively finished, and the NIH Program Officer's initial framing did not contradict that assumption. Planning to resubmit would generally be an appropriate response to a score of that level.

The client had largely written the application off. BW&CO had not.

BW&CO's Approach: Front Door and Back Door

BW&CO works NIH funding opportunities through two connected channels.

The front door is the proposal itself. This is where BW&CO develops and submits an application built to perform well under NIH peer review, addressing significance, innovation, approach, investigators, and environment in the way reviewers expect.

The back door is strategic Program Officer engagement after the review has already happened. This is not an attempt to bypass NIH's process or improperly influence a funding decision. It reflects a simpler fact: NIH funding decisions do not end the moment a peer-review score is issued. Program Officers retain a role in helping the Institute understand the technology, its fit with programmatic priorities, and what has changed since the application was submitted.

In this case, BW&CO recommended that the founder request a meeting with the Program Officer despite the borderline score. Ahead of that meeting, BW&CO coached the founder on how to approach the conversation, including identifying any new evidence or progress that had emerged since the original submission and preparing to discuss it where relevant. BW&CO then participated directly in the meeting and helped structure the discussion around the specific concerns reviewers had raised.

What Happened in the Program Officer Meeting

The meeting opened cautiously. The Program Officer explained that applicants scoring in this range should generally prepare to resubmit. He also explained something equally important: the Institute did not operate under a fixed payline, and it had discretion to look more closely at an application, weigh its own priorities, and evaluate the proposal through a programmatic lens rather than a strictly numeric one.

From there, BW&CO helped walk through the major reviewer concerns point by point, giving the founder room to explain how the company intended to address each one. The conversation also surfaced meaningful progress the company had made since the proposal was originally submitted.

By the end of the meeting, the Program Officer's tone had changed. He noted that the team appeared to have carefully considered the reviewers' feedback, and he invited the company to share relevant updated progress as it became available. He clarified that NIH was not requesting a formal rebuttal, but that updated information relevant to the project could be useful to the Institute's consideration of the application.

That shift in tone was the opening BW&CO had been working toward.

The Result: An Official Notice of Award

The company has since received an official Notice of Award for its NIH Phase I project. The application is being funded.

A founder who initially believed a score of 39 meant the opportunity was closed instead continued working it through the appropriate NIH channels, with BW&CO managing the strategy at every step. Both halves of the approach mattered: the proposal itself, and the post-review engagement that followed it.

Why This Case Matters for NIH SBIR Applicants

Many companies treat NIH SBIR as a process that ends the moment a proposal is submitted. Others assume that once a peer-review score arrives, the funding outcome is already decided. Neither assumption holds up consistently.

NIH Program Officers weigh more than a single numeric score. They can consider Institute priorities, portfolio fit, reviewer feedback, the scientific merit of the underlying opportunity, and relevant developments that occur while a funding decision is still in progress. That range of discretion is exactly why BW&CO pairs proposal development with strategic Program Officer engagement rather than treating the two as separate, disconnected steps.

Front Door: Build the strongest possible application for NIH peer review.

Back Door: Help the Program Officer understand why the technology matters to the Institute, how the applicant has responded to reviewer concerns, how the project aligns with programmatic priorities, and what relevant progress has occurred since submission.

In this case, a borderline score of 39 did not end with a resubmission plan. It ended with an official NIH Phase I Notice of Award, because the company followed a front-door, back-door approach all the way through.

Frequently Asked Questions

Does a low NIH impact score mean an SBIR application will not be funded?

Not necessarily. A low or borderline impact score, such as a score of 39, often signals that an application falls outside a typical funding range and that resubmission may be the expected next step. However, NIH Institutes do not operate under a strict fixed payline in every case, and Program Officers can weigh factors beyond the numeric score, including programmatic priorities and progress made after submission.

What is the role of an NIH Program Officer after a proposal is scored?

An NIH Program Officer helps the Institute evaluate an application in the context of its own priorities and portfolio, beyond the peer-review score alone. Applicants can request a conversation with the Program Officer to better understand reviewer feedback, clarify how the project fits the Institute's mission, and share relevant progress or updated information that may be useful to the Institute's consideration.

What does BW&CO mean by a "front door, back door" approach to NIH funding?

The front door refers to developing and submitting a strong application designed to perform well in NIH peer review. The back door refers to strategic engagement with the Program Officer after the review, helping the Institute understand the technology, how reviewer concerns are being addressed, and what progress has occurred since submission. Neither step replaces the other, and BW&CO treats them as a single connected strategy rather than separate options.

Should a company still meet with its Program Officer after a poor NIH score?

Meeting with a Program Officer after a borderline or low score can still be worthwhile. NIH Institutes can retain discretion to examine an application more closely, and a well-prepared conversation, focused on reviewer concerns and any new evidence of progress, can change how an Institute views the funding decision. Coming to that meeting prepared, rather than treating the score as final, is often what makes the difference.

FAQ

What is Olfera's OChip platform? OChip is an olfactory brain-on-chip developed by Olfera. It recreates the human nose-to-brain neural circuit inside a microfluidic system built for directional axonal connectivity, using primary human olfactory neurons collected non-invasively from living donors, including early-stage Parkinson's disease patients.

What NASA program funded this project? The project was funded through NASA's STTR (Small Business Technology Transfer) program, under the 2026B-I solicitation, subtopic ORBECON.2.T26B, Biotechnology Applications from Space for Earth.

Why study Parkinson's disease in microgravity? Microgravity has been shown to accelerate cellular aging, alpha-synuclein aggregation, and mitochondrial and dopamine pathway dysfunction. Because Parkinson's disease normally progresses over decades, these accelerated conditions compress the disease timeline into a window that is practical to study aboard the ISS.

Who is Olfera's research partner for the ISS validation work? Olfera is partnering with BioServe Space Technologies to validate the OChip platform aboard the International Space Station.

What role did BW&CO play in the proposal? BW&CO supported Olfera across the full proposal lifecycle, including strategy, initial drafting, technical review and editing, and compliance and administrative review ahead of submission. Kris Mueller led strategy and drafting as project consultant, and Barbara Serafin managed compliance and administrative review.

What is an STTR Phase I award? STTR Phase I is the initial, feasibility-stage award under the federal Small Business Technology Transfer program. It requires a formal partnership between a small business and a research institution, and it provides non-dilutive funding to establish technical merit and feasibility before a company can pursue a larger Phase II award.